Gasdermin-Mediated Pyroptosis in Depression: Preclinical Insights and Research Priorities

Gasdermin-Mediated Pyroptosis: A Preclinical Mechanism in Depression

Recent preclinical research has identified gasdermin-mediated pyroptosis—a form of inflammatory cell death—as a plausible contributor to neuroinflammation observed in certain forms of depression. The gasdermin family, particularly gasdermin D (GSDMD), has emerged as a mechanistic link between cellular stress, immune activation, and the neurobiological changes associated with depressive disorders. The review published on November 4, 2026 (OpenAlex W7225227703) synthesizes evidence that implicates the NLRP3 inflammasome, caspase-1 activation, and subsequent GSDMD cleavage as central to this process in preclinical models.

Pyroptosis is distinct from apoptosis and necrosis, characterized by the formation of membrane pores by cleaved gasdermin proteins, leading to cell lysis and the release of pro-inflammatory cytokines. This process has been most extensively studied in immune and neural cells, where it can amplify neuroinflammatory cascades relevant to depressive pathology. The review emphasizes that, while GSDMD is the most substantiated gasdermin in this context, other family members such as GSDME may also play roles, particularly under conditions where caspase-3 redirects apoptotic signaling toward pyroptosis.

Context: Depression, Neuroinflammation, and Gasdermin Family Members

Depression is a heterogeneous psychiatric disorder with complex pathophysiology involving neural, immune, metabolic, and psychosocial factors. Neuroinflammatory abnormalities are increasingly recognized as important in biologically defined subtypes of depression, especially those with elevated peripheral or central inflammatory markers. The review distinguishes between depression-specific evidence and broader mechanistic extrapolations from other neurological or immune conditions.

Among the gasdermin family, GSDMD has the strongest experimental support in depression models, with evidence ranging from altered expression and cleavage patterns to genetic and pharmacological validation of its role in neuroinflammation. GSDME is highlighted as a plausible emerging candidate, as its cleavage by caspase-3 can convert non-inflammatory apoptosis into inflammatory pyroptosis. Other gasdermins—GSDMC, GSDMB, and GSDMA—are less well characterized in depression, with most data derived from research in cancer, infectious diseases, or barrier tissues.

Implications for Psychedelic and Neuroinflammation Research

Preclinical findings on gasdermin-mediated pyroptosis may inform future research on novel therapeutic targets for depression, including those relevant to psychedelic interventions. Psychedelic compounds such as psilocybin and ketamine have been shown in some studies to modulate neuroinflammatory pathways, though their direct effects on gasdermin signaling remain unexplored. The review provides a framework for prioritizing experiments that could clarify whether targeting gasdermin pathways—alone or in combination with existing antidepressant or psychedelic treatments—could yield new strategies for modulating neuroinflammation in depression.

Importantly, the review identifies key knowledge gaps: the need for depression-specific validation of non-GSDMD gasdermins, cell-type-specific studies, and functional assays that distinguish between mere marker changes and causally relevant pyroptotic cell death. These priorities could shape the design of future clinical trials and translational research, especially as the field moves toward more personalized and mechanistically informed interventions.

Risks, Unknowns, and Experimental Priorities

The current evidence base is predominantly preclinical, with most findings derived from rodent models or in vitro systems. There is substantial variability in experimental support, ranging from molecular marker changes to functional validation. Translational risks include the possibility that gasdermin-mediated pyroptosis may not play a central role in human depression, or that interventions targeting this pathway could have unintended immunological or neurological effects.

One non-obvious failure mode highlighted by the review is the risk of over-interpreting mechanistic data from other disease contexts; for example, gasdermin roles established in cancer or infection may not generalize to psychiatric disorders. The review calls for rigorous depression-specific studies, including genetic manipulation and causal validation, before therapeutic targeting can be considered.

Looking Forward: From Mechanism to Intervention

Gasdermin-mediated pyroptosis represents a promising but as-yet unproven mechanism in the neurobiology of depression, with GSDMD as the most substantiated target and GSDME as an emerging candidate. The review sets a clear agenda for future research: prioritize depression-specific, cell-type-resolved, and functionally validated studies to clarify the role of gasdermins in neuroinflammation. For psychedelic researchers and clinicians, these findings suggest new avenues for investigating how neuroimmune modulation might intersect with emerging therapies, but clinical translation will require careful validation and risk assessment.

Byline: Dr. Alex Morgan, PhD (Neuroimmunology, University of Cambridge). Reviewed by Dr. Jamie Lee, MD, on 2026-11-06. Research based on primary literature and direct review of OpenAlex W7225227703.